Abstract
BACKGROUND AND PURPOSE: Corticosteroids such as triamcinolone acetonide (TAA) are potent drugs administered intra-articularly as an anti-inflammatory therapy to relieve pain associated with osteoarthritis (OA). However, the ability of early TAA intervention to mitigate OA progression and modulate immune cell subsets remains unclear. Here, we sought to understand the effect of early intra-articular injection of TAA on OA progression, local macrophages, and peripheral blood monocytes.
EXPERIMENTAL APPROACH: Degenerative joint disease was induced by intra-articular injection of collagenase into the knee joint of male C57BL/6 mice. After 1 week, TAA or saline was injected intra-articularly. Blood was taken throughout the study to analyse monocyte subsets. Mice were killed at days 14 and 56 post-induction of collagenase-induced OA (CiOA) to examine synovial macrophages and structural OA features.
KEY RESULTS: The percentage of macrophages relative to total live cells present within knee joints was increased in collagenase- compared with saline-injected knees at day 14 and was not altered by TAA treatment. However, at day 56, post-induction of CiOA, TAA-treated knees had increased levels of macrophages compared with the knees of untreated CiOA-mice. The distribution of monocyte subsets present in peripheral blood was not altered by TAA treatment during the development of CiOA. Osteophyte maturation was increased in TAA-injected knees at day 56.
CONCLUSION AND IMPLICATIONS: Intra-articular injection of TAA increases long-term synovial macrophage numbers and osteophytosis. Our findings suggest that TAA accentuates the progression of osteoarthritis-associated features when applied to an acutely inflamed knee.
Original language | English |
---|---|
Pages (from-to) | 2771-2784 |
Number of pages | 14 |
Journal | British Journal of Pharmacology |
Volume | 179 |
Issue number | 11 |
Early online date | 14 Dec 2021 |
DOIs | |
Publication status | Published - Jun 2022 |
Bibliographical note
Funding Information:This study was financially supported by Reumafonds ReumaNederland (grant no. 18‐1‐202) and the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska‐Curie grant agreement no. 721432 CarBon.
Funding Information:
The authors would like to thank Sita Bierma-Zeinstra, Koen Bos, and Jos Runhaar for discussion on clinical background and Yanto Ridwan, for his technical assistance with ?CT imaging. This work was performed within the framework of the Erasmus Postgraduate School Molecular Medicine. This study was financially supported by Reumafonds ReumaNederland (grant no. 18-1-202) and the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sk?odowska-Curie grant agreement no. 721432 CarBon.
Publisher Copyright:
© 2022 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.